QIAGEN
200 Hathersage Rd, Manchester
Manchester
M13 0BH
View on map
0808 234 3974
Get here sustainably

QIAGEN, a global leader in molecular testing and clinical diagnostics, established its UK presence in 2009 by acquiring DxS, a pioneering diagnostics company based at the Manchester Incubator Building on Grafton Street. The acquisition, supported by MIDAS (Manchester’s inward investment agency), was driven by Manchester’s thriving life sciences ecosystem and strong growth potential.
Since then, QIAGEN’s integration and evolution in Manchester have been marked by steady expansion. Initially, DxS was assimilated into QIAGEN’s global business activities to spearhead the development of companion diagnostics to help guide treatment decisions, particularly for cancer patients. Over time, the site developed into a critical innovation engine, growing its R&D and commercial capabilities and adding specialised functions in clinical affairs, regulatory and quality assurance. Today, QIAGEN’s Manchester team has about 350 professionals and growing.
QIAGEN’s UK headquarters are now based at Citylabs 2.0, a state-of-the-art biomedical facility that houses QIAGEN’s Global Centre of Excellence for Precision Medicine. This location not only anchors their UK strategy but also plays a central role in shaping global diagnostics innovation.
QIAGEN serves over 500,000 customers worldwide, delivering “Sample to Insight” solutions that help its customers make improvements in life possibly by gaining insights into the building blocks of life – DNA, RNA, and proteins.
Manchester, and specifically the Oxford Road Corridor, was chosen as the company’s UK hub for its direct access to scientific talent and research excellence at the University of Manchester.
This relationship has grown to include annual undergraduate placements and contributions to academic programs such as the Molecular Diagnostics course.
In July 2022, QIAGEN deepened its collaboration with Manchester University NHS Foundation Trust (MFT) through a Memorandum of Understanding (MoU), enabling cross-disciplinary knowledge exchange between clinicians and diagnostic experts. Collaborative opportunities within the campus ecosystem have also fueled innovation; during the COVID-19 pandemic, QIAGEN partnered with Affinity Biomarker Solutions and the University of Manchester to support patient testing using high-throughput automation platforms—simultaneously running routine PCR diagnostics and introducing new commercial tests.


